Singapore, May 23 -- Qiagen has announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customised molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.

The combination of Qiagen's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen Qiagen's position in oncology research.

Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on Qiagen's QIAcuity platforms. These assays are optimised to simultaneously detect multiple mutations in cell...